Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis

References

• American Diabetes Association. Standards of Medical Care in Diabetes – 2007. Diabetes Care 2007;30:S4–41
   PubMedGoogle Scholar
• Rydén L, Standl E, Bartnik M, Van den Berghe G on behalf of the Task Force Members. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88–136
   Google Scholar
• IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23: 579–93
   Google Scholar
• Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006;32:7–13
   PubMed Web of Science ®Google Scholar
• Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006;32:910–17
   PubMed Web of Science ®Google Scholar
• Hayes RP, Bowman L, Monahan PO, et al. Understanding diabetes medications from the perspective of patients with type 2 diabetes: Prerequisite to medication concordance. Diabetes Educ 2006;32:404–14
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl 2005;7:L21–6
   Google Scholar
• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22: 331–9
   Google Scholar
• Valsamakis G, Chetty RK, Kumar S. The management of obesity in type 2 diabetes mellitus. Curr Med Res Opin 2002;18\(Suppl 1):S75–81
   Google Scholar
• Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9:S326–34
   PubMedGoogle Scholar
• Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397–415
   PubMed Web of Science ®Google Scholar
• Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001;50:583–9
   PubMed Web of Science ®Google Scholar
• Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117: 77–88
   Google Scholar
• Zinman B, Hoogwerf B, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477–85
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259–67
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139–53
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143: 559–69
   Google Scholar
• DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated subjects with type 2 diabetes mellitus. Diabetes Care 2005;28:1092–100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in subjects with type 2 diabetes mellitus treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated subjects with type 2 diabetes. Diabetes Care 2004;27:2628–35
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082–9
   PubMed Web of Science ®Google Scholar
• Edwards CMB, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001;281:E155–61
   PubMed Web of Science ®Google Scholar
• Consensus Development Conference, National Institute of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults – the evidence report. Obes Res 1998;6(Suppl 2):S51–209
   Google Scholar
• Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond) 2006;30:391–9
   PubMed Web of Science ®Google Scholar
• Riddle MC, Henry RR, Poon TH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006;22:483–91
   PubMed Web of Science ®Google Scholar
• Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight subjects with type 2 diabetes. Diabetes Obes Metab 2006;8:436–47
   PubMed Web of Science ®Google Scholar
• Effect of AC2993 (synthetic exendin-4) compared with insulin glargine in patients with type 2 diabetes also using combination therapy with sulfonylurea and metformin. Eli Lilly Clinical Trial Registry Summary, 2007. Available at: http://lillytrials.com/results/by_ta/results_diab.html
   Google Scholar
• Efficacy of exenatide (AC2993, synthetic exendin-4, LY2148568) compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulfonylurea and metformin. Eli Lilly Clinical Trial Registry Summary, 2007. Available at: http://lillytrials.com/results/by_ta/results_diab.html
   Google Scholar